BGNE Stock Overview
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
BeiGene, Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$131.96 |
52 Week High | US$266.67 |
52 Week Low | US$131.28 |
Beta | 0.63 |
1 Month Change | -21.50% |
3 Month Change | -17.41% |
1 Year Change | -48.90% |
3 Year Change | -57.58% |
5 Year Change | 9.22% |
Change since IPO | 365.96% |
Recent News & Updates
Recent updates
BeiGene Still Bleeding Red Ink Despite Blockbuster Drug
Mar 08BeiGene, Ltd.'s (NASDAQ:BGNE) Intrinsic Value Is Potentially 26% Above Its Share Price
Jan 31Here's Why BeiGene (NASDAQ:BGNE) Can Manage Its Debt Despite Losing Money
Oct 16Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation?
Jul 11Rock star Growth Puts BeiGene (NASDAQ:BGNE) In A Position To Use Debt
Jun 19Revenues Not Telling The Story For BeiGene, Ltd. (NASDAQ:BGNE)
Apr 17A Look At The Fair Value Of BeiGene, Ltd. (NASDAQ:BGNE)
Mar 24Is BeiGene (NASDAQ:BGNE) Using Debt Sensibly?
Dec 07BeiGene upgraded to buy at Guggenheim on improved confidence in Brukinsa potential
Oct 13EMA panel recommends extending indication for BeiGene's cancer drug Brukinsa
Sep 16Shareholder Returns
BGNE | US Biotechs | US Market | |
---|---|---|---|
7D | -9.7% | -4.2% | -3.7% |
1Y | -48.9% | -2.0% | 20.5% |
Return vs Industry: BGNE underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: BGNE underperformed the US Market which returned 20.5% over the past year.
Price Volatility
BGNE volatility | |
---|---|
BGNE Average Weekly Movement | 7.5% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.4% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BGNE's share price has been volatile over the past 3 months.
Volatility Over Time: BGNE's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 10,600 | John Oyler | www.beigene.com |
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic.
BeiGene, Ltd. Fundamentals Summary
BGNE fundamental statistics | |
---|---|
Market cap | US$13.79b |
Earnings (TTM) | -US$881.71m |
Revenue (TTM) | US$2.46b |
5.6x
P/S Ratio-15.6x
P/E RatioIs BGNE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BGNE income statement (TTM) | |
---|---|
Revenue | US$2.46b |
Cost of Revenue | US$543.47m |
Gross Profit | US$1.92b |
Other Expenses | US$2.80b |
Earnings | -US$881.71m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 11, 2024
Earnings per share (EPS) | -8.44 |
Gross Margin | 77.90% |
Net Profit Margin | -35.86% |
Debt/Equity Ratio | 25.0% |
How did BGNE perform over the long term?
See historical performance and comparison